Tumor Promoting Function of DUSP10 in Non-Small Cell Lung Cancer Is Associated With Tumor-Promoting Cytokines.
Cytokine
Dual specificity phosphatase
Mitogen-activated protein kinases
Non-small cell lung cancer
Journal
Immune network
ISSN: 1598-2629
Titre abrégé: Immune Netw
Pays: Korea (South)
ID NLM: 101137270
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
30
04
2023
revised:
09
07
2023
accepted:
31
07
2023
medline:
6
9
2023
pubmed:
6
9
2023
entrez:
6
9
2023
Statut:
epublish
Résumé
Lung cancer, particularly non-small cell lung cancer (NSCLC) which contributes more than 80% to totally lung cancer cases, remains the leading cause of cancer death and the 5-year survival is less than 20%. Continuous understanding on the mechanisms underlying the pathogenesis of this disease and identification of biomarkers for therapeutic application and response to treatment will help to improve patient survival. Here we found that a molecule known as DUSP10 (also known as MAPK phosphatase 5) is oncogenic in NSCLC. Overexpression of DUSP10 in NSCLC cells resulted in reduced activation of ERK and JNK, but increased activation of p38, which was associated with increased cellular growth and migration. When inoculated in immunodeficient mice, the DUSP10-overexpression NSCLC cells formed larger tumors compared to control cells. The increased growth of DUSP10-overexpression NSCLC cells was associated with increased expression of tumor-promoting cytokines including IL-6 and TGFβ. Importantly, higher DUSP10 expression was associated with poorer prognosis of NSCLC patients. Therefore, DUSP10 could severe as a biomarker for NSCLC prognosis and could be a target for development of therapeutic method for lung cancer treatment.
Identifiants
pubmed: 37670811
doi: 10.4110/in.2023.23.e34
pmc: PMC10475826
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e34Informations de copyright
Copyright © 2023. The Korean Association of Immunologists.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors declare no potential conflicts of interest.
Références
Am J Respir Cell Mol Biol. 2002 May;26(5):558-64
pubmed: 11970907
Cancer Cell. 2018 Jun 11;33(6):1094-1110.e8
pubmed: 29805078
FEBS J. 2013 Jan;280(2):489-504
pubmed: 22812510
Nat Commun. 2021 Apr 16;12(1):2284
pubmed: 33863904
Nat Genet. 2007 Jun;39(6):741-9
pubmed: 17468757
Cell Biochem Biophys. 2015 May;72(1):165-9
pubmed: 25548002
Nature. 2004 Aug 12;430(7001):793-7
pubmed: 15306813
Clin Chest Med. 2020 Mar;41(1):1-24
pubmed: 32008623
Immune Netw. 2016 Apr;16(2):85-98
pubmed: 27162525
Oncogenesis. 2018 Jan 17;7(2):1
pubmed: 29367650
Oncogene. 2016 Jan 14;35(2):206-17
pubmed: 25772234
Heliyon. 2023 Mar 24;9(4):e14799
pubmed: 37025861
BMC Med. 2022 May 13;20(1):187
pubmed: 35550592
Transl Lung Cancer Res. 2016 Jun;5(3):288-300
pubmed: 27413711
BMC Cancer. 2019 Jul 15;19(1):691
pubmed: 31307405
Ann Palliat Med. 2021 Jan;10(1):202-209
pubmed: 33545757
Annu Rev Pathol. 2011;6:49-69
pubmed: 20887192
Oncogene. 2020 Apr;39(14):2890-2904
pubmed: 32029901
Cancer Res. 2000 May 1;60(9):2535-40
pubmed: 10811136
Cancer Res. 2012 May 15;72(10):2457-67
pubmed: 22589270
Cancer Cell. 2007 Feb;11(2):191-205
pubmed: 17292829
Oncogene. 2018 Jun;37(24):3183-3199
pubmed: 29540830
Cell Res. 2009 Jan;19(1):128-39
pubmed: 19114990
Int J Mol Sci. 2021 Aug 12;22(16):
pubmed: 34445366
Nat Rev Mol Cell Biol. 2020 Oct;21(10):607-632
pubmed: 32576977
Cancer Sci. 2007 Jul;98(7):1048-54
pubmed: 17511773